The author highlights positive pancreatic cancer clinical data for Marker Therapeutics.
MRKR β LONG Author highlights positive Baylor study data showing 84.6% disease control and median OS 14.1 months in pancreatic cancer, implying a bullish signal for Marker Therapeutics. The safety profile and T-cell persistence support the clinical benefit.
$MRKR PANCREATIC CANCER SIGNAL πππ
$MRKR SHOWS PANCREATIC CANCER SIGNAL
πΉ Baylor study shows 84.6% disease control in pancreatic cancer (Arm A) πΉ Favorable safety profile combining T-cell therapy with chemotherapy πΉ Median response 7.5 months; median OS 14.1 months πΉ Clinical benefit linked to persistence of targeted T cells up to 12 months
This Reddit post, published January 06, 2026, features u/Chance-Ocelot6436 discussing MRKR. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Chance-Ocelot6436 · Tickers: MRKR